Description of Lymphatic Damage in Encephalic Venous Thrombosis and Strictures in MRI a Reverse-recovery Sequence: a Pilot Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05041569

Acronym

ALTREVE

Enrollment

100

Registered

2021-09-13

Start date

2021-12-17

Completion date

2026-12-01

Last updated

2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRI

Brief summary

Inclusion (J0): * Information * Verification of inclusion and non-inclusion criteria * Collection of consent * MRI examination with injection of contrast product as part of the treatment comprising the sequences: T1 TFE 1.0 iso 3D FLAIR injected Injected elliptical venous angiography 0.4mm iso or less 3D SWIp multiecho 3D T1 injected FABIR iso without injection (added as part of care in case of suspected ASH or meningitis) FLAIR 1.0 without injection (added as part of care for suspected ASH or meningitis) T2 BFFE XD (added by search) FABIR iso injected (added by research) 3D PD T1 0.55 MSDE iso injected (added by research) Clinical information (SRM on inclusion, on discharge and at 3 months and recurrence within the year) will be collected from the patient's medical file

Interventions

OTHERMRI sequences

perform additional sequences added by research

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 years of age * Performing an MRI injected as part of care for one of the following reasons: * suspicion of pathology likely to be associated with narrowing or obstruction of one or more venous sinuses (cerebral thrombophlebitis, tissue damage with venous extension, idiopathic HIC * venous narrowing or obstruction proven by one of the above pathologies, requiring as part of routine care an injected MRI (search for impact, monitoring, pre-therapeutic assessment or prognosis) * Express consent to participate in the study * Affiliate or beneficiary of a social security scheme

Exclusion criteria

* Absolute contraindication to MRI * Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman

Design outcomes

Primary

Measure	Time frame	Description
Using a new MRI sequence for the detection of lymph nods	1 DAY	Inversion recovery pulse sequences in MRI will be used to detect lymph nods.

Countries

France

Contacts

CONTACTamélie YAVCHITZ

ayavchitz@for.paris0148036454

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026